Novo Nordisk (NYSE: NVO) just made a partnership play worth $600 million with a small biotech called NanoVation that might just change the stock's trajectory for many years to come. On Sept.

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...

Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The ...

BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...

Nov. 1, 2024 — Microplastics have been steadily increasing in freshwater environments for decades and are directly tied to rising global plastic production since the 1950s, according to a new ...

Nov. 6, 2024 — Sewage surveillance is emerging as a powerful tool in the fight against antimicrobial resistance with the potential to protect vulnerable communities more ... Nov. 6, 2024 ...

MarketBeat Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines ...

who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...